Online inquiry

IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4757MR)

This product GTTS-WQ4757MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets SOST gene. The antibody can be applied in Osteogenesis imperfecta (OI) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_025237.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50964
UniProt ID Q9BQB4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4757MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14119MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ11387MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ5524MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ2117MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ13413MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ4716MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ3316MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ6521MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CX-191
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW